WHO 2级脑膜瘤放射外科治疗结局:Ki-67指数在指导肿瘤边缘剂量中的作用
单中心回顾性分析2011至2023年99例病理证实的WHO 2级脑膜瘤接受立体定向放射外科(SRS)的结局。中位随访49个月,中位总生存119个月,中位无进展生存40个月,9%出现不良事件。Ki-67>10%者肿瘤局部边缘进展风险为Ki-67≤10%者的2.17倍(P=.018);Ki-67>10%肿瘤中边缘剂量≥14 Gy与更好的肿瘤控制相关。
要点
- WHO 2级脑膜瘤SRS后中位总生存119个月,中位无进展生存40个月。
- Ki-67>10%者局部边缘进展风险为Ki-67≤10%者的2.17倍(P=.018)。
- Ki-67>10%肿瘤中边缘剂量≥14 Gy与显著更好的肿瘤控制相关。
核心结论
- WHO 2级脑膜瘤管理需多学科综合治疗。
- 本研究显示靶向SRS对病变有限的患者有价值,并进一步确立可指导个体化计划的预测性生物标志物。
研究设计与样本
- 单中心连续病例回顾性队列,纳入2011至2023年病理证实的WHO 2级脑膜瘤接受SRS者99例,中位年龄62岁,其中11例接受5次大分割SRS,22例曾接受放疗。
主要发现
- 中位随访49个月,中位总生存119个月(95%CI 92-NA),估计5年和10年生存率分别为83%和27%。
- 中位无进展生存40个月(95%CI 32-62),3年和5年无进展生存率分别为54%和35%。
- 中位局部边缘无进展生存63个月(95%CI 51.8-NA),3年和5年局部边缘无进展生存率分别为65%和52%。
- 9例(9%)发生不良事件,其中2例为常见不良事件评价标准3级、7例为2级,均为水肿导致的神经功能缺损加重。
- 单次SRS队列中,Ki-67显著预测总生存和颅内无进展生存;校正协变量后,Ki-67>10%肿瘤局部边缘进展风险为Ki-67≤10%者的2.17倍(P=.018)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The management of World Health Organization (WHO) grade 2 meningiomas is complicated by their diverse clinical behaviors. Stereotactic radiosurgery (SRS) can be an effective management option. Literature on SRS dose selection is limited but suggests that a higher dose is better for tumor control. We characterize the predictors of post-SRS outcomes that can help guide planning and management. METHODS: We reviewed a cohort of consecutive patients with pathologically-proven WHO grade 2 meningiomas who underwent SRS at a single institution between 2011 and 2023. RESULTS: Ninety-nine patients (median age 62 years) underwent SRS, 11 of whom received hypofractionated SRS in 5 fractions. Twenty-two patients had received previous irradiation. The median follow-up was 49 months. The median overall survival was 119 months (95% CI 92-NA) with estimated 5- and 10-year survival of 83% and 27%, respectively. The median progression-free survival (PFS) was 40 months (95% CI 32-62), with 3- and 5-year rates at 54% and 35%, respectively. The median locomarginal PFS was 63 months (95% CI 51.8-NA) with 3- and 5-year rates at 65% and 52%. Nine (9%) patients experienced adverse events, 2 Common Terminology Criteria for Adverse Events grade 3 and 7 grade 2, consisting of worsening neurologic deficit from edema. In the single-session cohort, Ki-67 significantly predicted both overall survival and intracranial PFS. Tumors with Ki-67 >10% had 2.17 times the risk of locomarginal progression compared with Ki-67 ≤10% ( P = .018) adjusting for covariates. Sex, prescription dose, tumor volume, and location also predicted tumor control. In tumors with Ki-67 >10%, margin dose ≥14 Gy was associated with significantly better tumor control but not for tumors with Ki-67 ≤10%. CONCLUSION: The management of WHO grade 2 meningiomas requires a multimodality approach. This study demonstrates the value of a targeted SRS approach in patients with limited disease and further establishes predictive biomarkers that can guide planning through a personalized approach.
引用
- Meng Y, Bernstein K, Mashiach E, et al. Outcomes of Radiosurgery for WHO Grade 2 Meningiomas: The Role of Ki-67 Index in Guiding the Tumor Margin Dose. Neurosurgery. 2024. PMID: 39526756. doi:10.1227/neu.0000000000003255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。